Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

CB, Creech; RW Jr, Frenck; EA, Sheldon; DJ, Seiden; MK, Kankam; ET, Zito; D, Girgenti; JM, Severs; FW, Immermann; LK, McNeil; D, Cooper; KU, Jansen; W, Gruber; J, Eiden; AS, Anderson; J, Baber

doi:10.1016/j.vaccine.2016.11.032

Public

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.

Shared by NobleBlocks on Nov 17, 2016 • 12:00 AM UTC

Authors:

Creech CB

Frenck RW Jr

Sheldon EA

Abstract

<h4>Background</h4>The decline in immune function with age is a challenge to vaccine development. Following an initial study in adults aged 18-64years, this study evaluated the safety and immunogenicity of Staphylococcus aureus (S. aureus) 4-antigen (SA4Ag) and 3-antigen (SA3Ag) vaccine in older adu...

Subject

Staphylococcus aureus

Vaccine

Clumping Factor A

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!